Progyny Inc. Common Stock (PGNY)
Stock · NASDAQ · Health Care
$26.86as of 10/16/2026
Price chart
Active signals
PGNY Signal Track Record
How signals performed across all stocks →What PGNY's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 35 | -2.2% | 46% | October 7, 2026 |
| Bollinger Band Breakdown | 25 | +0.8% | 52% | September 29, 2026 |
| Bollinger Band Breakout | 21 | -3.6% | 43% | September 8, 2026 |
| 200-Day Moving Average TouchActive now | 16 | -3.7% | 38% | February 4, 2026 |
| Any 20-session window (baseline) | -0.5% | 48% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About PGNY
Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. The company also offers Progyny Rx, an integr…
- Sector
- Health Care
- Industry
- Misc Health and Biotechnology Services
- Employees
- 835
- Website
- www.progyny.com/
Fundamentals
- 1-day range
- $25.81$28.04
- Market cap
- $2.37B
- P/E (trailing)
- 25.32
- P/E (forward)
- 12.01
- EPS (trailing)
- $0.92
- Dividend yield
- —
- Beta
- 0.99
- Avg. volume
- 1.14M
How Progyny Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 27, 2026 · via SEC EDGAR / Finnhub
Forecasts
12 analyst ratings
Progyny Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- PGNYProgyny Inc. Common Stock$26.86▼ 2.17%Market cap $2.37BP/E 25.32$16.1$33.07
- AGLagilon health inc. Common Stock$85.12▼ 3.76%Market cap $1.45BP/E —$7.48$133.04
- VMDViemed Healthcare Inc. Common Shares$9.48▼ 2.77%Market cap $362.60MP/E 25.72$6.05$12.61
- PARKPark Dental Partners Inc. Common Stock$18.95▼ 1.33%Market cap $96.71MP/E —$9.53$26.79
- CCELCryo-Cell International Inc. Common Stock$4.42▲ 21.10%Market cap $28.78MP/E —$2.72$4.9
- MGRXMangoceuticals Inc. Common Stock$0.29▼ 9.66%Market cap $10.31MP/E —$0.162$2.75
- NIVFNewGenIvf Group Limited Class A Ordinary Shares$0.279▲ 11.60%Market cap $3.36MP/E 0.18$0.1722$24,624
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| PGNY Progyny Inc. Common Stock | $2.37B | 25.32 | $26.86 | ▼ 2.17% | $16.1$33.07 |
| AGL agilon health inc. Common Stock | $1.45B | — | $85.12 | ▼ 3.76% | $7.48$133.04 |
| VMD Viemed Healthcare Inc. Common Shares | $362.60M | 25.72 | $9.48 | ▼ 2.77% | $6.05$12.61 |
| PARK Park Dental Partners Inc. Common Stock | $96.71M | — | $18.95 | ▼ 1.33% | $9.53$26.79 |
| CCEL Cryo-Cell International Inc. Common Stock | $28.78M | — | $4.42 | ▲ 21.10% | $2.72$4.9 |
| MGRX Mangoceuticals Inc. Common Stock | $10.31M | — | $0.29 | ▼ 9.66% | $0.162$2.75 |
| NIVF NewGenIvf Group Limited Class A Ordinary Shares | $3.36M | 0.18 | $0.279 | ▲ 11.60% | $0.1722$24,624 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- 3 Profitable Stocks with Warning SignsYahoo · 9/24/2026
- Progyny (NASDAQ:PGNY): A Quality Investing Watchlist CandidateChartMill · 9/21/2026
- PGNY vs. CRL: Which Stock Is the Better Value Option?Yahoo · 9/18/2026
- Progyny (PGNY) Stock Looks Fairly Valued Despite Its 57% Five Year SlideYahoo · 9/18/2026
- Progyny: Best-In-Class And Likely To Exceed Analyst Estimates In 2027SeekingAlpha · 9/17/2026
- Concentra Group Holdings Parent, Inc. (CON) Hits Fresh High: Is There Still Room to Run?Yahoo · 9/15/2026
- Options Movement At Progyny: KEVIN GORDON Exercises Worth $325KBenzinga · 9/15/2026
Insider Activity
Insider Actions →- Allison Swartz · September 23, 2026 · Sale3.9K @ $26.1
- Geoffrey Clapp · September 17, 2026 · Tax Withholding819 @ $27.38
- Kevin K. Gordon · September 10, 2026 · Option Exercise22.0K @ $13
- Kevin K. Gordon · September 10, 2026 · Sale11.5K @ $27.12
- Kevin K. Gordon · September 10, 2026 · Tax Withholding10.5K @ $27.24
- Allison Swartz · September 4, 2026 · Tax Withholding479 @ $26.61
- Mark S. Livingston · September 4, 2026 · Tax Withholding479 @ $26.61
- Peter Anevski · September 3, 2026 · Tax Withholding5.4K @ $26.29
- Allison Swartz · September 3, 2026 · Tax Withholding828 @ $26.29
- Mark S. Livingston · September 3, 2026 · Tax Withholding1.5K @ $26.29
- Mark S. Livingston · September 2, 2026 · Tax Withholding224 @ $25.66
- Allison Swartz · August 28, 2026 · Tax Withholding1.4K @ $25.86
- Melissa B. Cummings · July 14, 2026 · Tax Withholding1.2K @ $31.98
- Melissa B. Cummings · July 14, 2026 · Sale2.2K @ $31.6
- Geoffrey Clapp · June 17, 2026 · Tax Withholding819 @ $26.6
Institutional Ownership
March 31, 2026
- Total shares held
- 75.72M
- Total value held
- $1.27B
- Institutional holders
- 289
- Unknown12.00M
- Unknown6.50M
- Unknown5.29M
- Unknown3.08M
- Unknown2.83M
- Unknown2.69M
- Unknown2.29M
- Unknown2.29M
- Unknown2.07M
- Unknown2.04M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Progyny (PGNY) shares rise over 6% amid record sales pace
Shares of Progyny jumped about 6% after the company reported a selling season that is pacing toward a record level. Analysts noted the move while also comparing the stock’s valuation to peers such as CRL. The price action comes as the stock trades with an RSI near 61 and holds above a support level around $25.40. The news adds to recent discussion about potential upside, though the stock remains below its 52‑week high.
Progyny (PGNY) shares rise over 6% amid record sales pace. Shares of Progyny jumped about 6% after the company reported a selling season that is pacing toward a record level. Analysts noted the move while also comparing the stock’s valuation to peers such as CRL. The price action comes as the stock trades with an RSI near 61 and holds above a support level around $25.40. The news adds to recent discussion about potential upside, though the stock remains below its 52‑week high.